Recent updates concerning IGC Pharma center primarily on the progress of its clinical trials evaluating proprietary drug candidates targeting neurodegenerative disorders, regulatory interactions with health authorities, and periodic financial results filings. The company continues to advance its research initiatives in biotechnology while managing operational expenses, seeking strategic partnerships, and updating shareholders on research milestones through official corporate press releases and regulatory disclosures filed with financial market supervisors.